

filed, other than the manager filing this report.

[If there are no entries in this list, state "NONE" and omit the column headings and list entries.]

NONE

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL

OMB Number: 3235-0006
 Estimated average burden
 hours per response: 23.8

COLUMN 1	COLUMN 2	COLUMN 3	COLUMN 4	COLUMN 5	COLUMN 6	COLUMN 7	COLUMN 8					
NAME OF ISSUER	TITLE OF CLASS	CUSIP	FIGI	VALUE (to the nearest dollar)	SHRS OR PRN AMT	SH/ PRN	PUT/ CALL	INVESTMENT DISCRETION	OTHER MANAGER	VOTING AUTHORITY		
										SOLE	SHARED	NONE
Adicet Bio, Inc.	Common Stock	007002108		590,592	968,183	SH		SOLE		968,183	0	0
Adverum Biotechnologies, Inc.	Common Stock	00773U207		388,954	180,909	SH		SOLE		180,909	0	0
Alnylam Pharmaceuticals, Inc.	Common Stock	02043Q107	1,449,289,070	4,444,445	4,444,445	SH		SOLE		4,444,445	0	0
Intellia Therapeutics, Inc.	Common Stock	45826J105		34,734,093	3,702,995	SH		SOLE		3,702,995	0	0